A promising experimental pill is giving new hope to patients battling advanced pancreatic cancer after researchers reported that the drug significantly extended survival times in one of the largest breakthroughs the disease has seen in decades. The medication, called daraxonrasib, targets a genetic mutation responsible for fueling tumor growth in the vast majority of pancreatic cancer cases. Researchers say the results could potentially change the future of treatment for one of the deadliest forms of cancer.
According to findings presented at the American Society of Clinical Oncology conference in Chicago and published in the New England Journal of Medicine, the drug was tested in a large clinical trial involving approximately 500 patients with metastatic pancreatic cancer whose disease had already stopped responding to previous treatments. Patients were randomly assigned to receive either daraxonrasib or additional chemotherapy.
Researchers found that patients taking daraxonrasib survived for a median of 13.2 months, compared to just 6.7 months for patients receiving chemotherapy. The results effectively doubled survival time and marked the first time a treatment has demonstrated such a substantial advantage over standard chemotherapy in previously treated metastatic pancreatic cancer patients.
Dr. Zev Wainberg of UCLA, one of the study’s lead researchers, described the findings as a major advancement. While he stressed that the drug is not a cure, he said it represents a significant step forward in a cancer type that has historically been extremely difficult to treat.
The drug works by targeting KRAS mutations, a major driver of pancreatic cancer growth. More than 90% of pancreatic cancer cases involve mutated KRAS proteins, which help tumors grow and spread. For decades, scientists struggled to develop treatments capable of effectively targeting this mutation because of the protein’s structure, causing it to be labeled “undruggable.”
Daraxonrasib was developed by Revolution Medicines and uses a mechanism researchers describe as similar to a molecular glue. The drug binds to multiple KRAS mutation subtypes and blocks the signals that allow cancer cells to continue growing. Researchers believe this broader targeting ability is one reason the drug has shown such promising results.
In addition to extending survival, patients taking the drug generally experienced fewer severe side effects than those receiving chemotherapy. Researchers reported that many participants experienced less pain, better overall quality of life, and shrinking tumors while receiving treatment. Several patients continued taking the medication even after study data was analyzed because they were still benefiting from it.
Dr. Rachna Shroff of the University of Arizona Cancer Center, who was not involved in the study, described the results as emotional and unprecedented. She said that after treating pancreatic cancer patients for 16 years, she was moved to tears when she first reviewed the trial findings. Shroff noted that many patients remained on the treatment because it was delivering meaningful and lasting benefits.
Researchers also found that patients taking daraxonrasib stayed on treatment significantly longer than patients receiving chemotherapy. Because many participants remain on the drug and continue responding positively, scientists believe the survival advantage could potentially grow larger as follow-up monitoring continues.
Dr. Brian Wolpin of the Dana-Farber Cancer Institute presented the study results and said daraxonrasib has the potential to become a new standard of care for previously treated metastatic pancreatic cancer patients. Researchers are now exploring whether the drug could be used earlier in treatment and whether shrinking tumors might help more patients qualify for surgery.
While the treatment showed strong results, researchers reported several side effects. The most common included skin rashes, which could sometimes become severe, along with mouth sores. Additional side effects observed during testing included nausea and inflammation. Despite these issues, researchers said most side effects were considered manageable, and relatively few patients stopped treatment because of them.
The study was funded by Revolution Medicines, which is seeking regulatory approval for the drug. The U.S. Food and Drug Administration has already begun expediting its review process. Federal regulators have additionally granted expanded-access authorization, allowing eligible patients to receive the drug before formal approval is completed.
Public interest in daraxonrasib increased after former U.S. Senator Ben Sasse publicly discussed his own experience taking the drug while battling stage 4 pancreatic cancer. Sasse previously described experiencing reduced pain and tumor shrinkage while on the treatment, though he also spoke openly about difficult side effects. Oncologists across the country have reportedly been flooded with inquiries from patients seeking access to the medication.
Pancreatic cancer remains one of the deadliest forms of cancer largely because it is often not detected until it has already spread to other parts of the body. The American Cancer Society estimates that approximately 67,000 Americans will be diagnosed with pancreatic cancer this year and more than 52,000 people will die from the disease. The current five-year survival rate is only about 13%.
Unlike several other major cancers that now have numerous targeted therapies and treatment options, pancreatic cancer has historically been far more difficult to treat. Researchers and cancer specialists say the success of daraxonrasib may signal the beginning of a major shift in how the disease is managed.
Experts not involved in the study called the findings a potential turning point. Some described the results as “landscape-changing,” while others referred to the drug as a “gamechanger” and one of the most important advances in pancreatic cancer treatment in decades.
Researchers also believe the science behind daraxonrasib could eventually help patients battling other cancers. KRAS mutations play a role in several types of cancer, including lung, colon, and certain gynecological cancers. Similar drugs are already being studied in additional clinical trials targeting those diseases.
Scientists are additionally investigating other approaches involving KRAS-targeted therapies, including cancer vaccines designed to train the immune system to recognize and attack cancer cells carrying these mutations. Researchers hope future combinations of targeted drugs, surgery, immunotherapy, and vaccines could further improve outcomes for pancreatic cancer patients.
Although researchers caution that the drug’s effects eventually decline as tumors develop resistance, many specialists believe daraxonrasib represents one of the most important advances the pancreatic cancer field has seen in years. For patients facing a disease long associated with limited treatment options and poor survival rates, the results are providing a level of optimism rarely seen in pancreatic cancer research.
Source: ABC15 Phoenix
